NVS Gains EC Approval for SMA Therapy Itvisma in Broad Population

RegulatoryapprovedItvismaPositive

AI Analysis

Summary

Novartis received European Commission approval for Itvisma (spinal muscular atrophy therapy) in a broad population. This regulatory milestone expands the therapy's market access in Europe.

Outcome Details

European Commission approval for Itvisma in broad population

Importance:8/10

Sentiment:

0.85

regulatory approvalEuropeSMA therapyEC approval

Related Companies

$NVS

Read the original article

Published by yahoo_finance on July 2, 2026 6:13 PM

Read Original